Additional Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    New York NY. 10029
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Chicago IL. 60611
    View Details

  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

    Xentria Investigative Site
    Greenville NC. 27858
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    UCLA Health Westwood Medical Plaza
    Westwood CA. 90095
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Chicago IL. 60153
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Salt Lake City UT. 84112
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    San Diego CA. 92093
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Houston TX. 77204
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Chicago IL. 60611
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    New York NY. 10027
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Richmond VA. 23284
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Miami FL. 33146
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Dallas TX. 75204
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Oklahoma City OK. 73104
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Chicago IL. 60612
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Charleston SC. 29425
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Los Angeles CA. 90024
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Cleveland OH. 44195
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    New Orleans LA. 70115
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    UCLA Health Westwood Medical Plaza
    Westwood CA. 90095
    View Details